A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY-318).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. TPS3105-TPS3105 ◽  
Author(s):  
J. Randolph Hecht ◽  
Aleix Prat ◽  
Miklos Pless ◽  
Antonio Cubillo ◽  
Aitana Calvo ◽  
...  
Author(s):  
J Randolph Hecht ◽  
Steven Raman ◽  
Daniel Y Sze ◽  
A Craig Lockhart ◽  
Rebecca A Moss ◽  
...  

2001 ◽  
Vol 45 (2) ◽  
pp. 147
Author(s):  
Jeong Nam Heo ◽  
Hyun Chul Rhim ◽  
Yong Soo Kim ◽  
Byung Hee Koh ◽  
On Koo Cho ◽  
...  

Author(s):  
Deniz Nart ◽  
Banu Yaman ◽  
Serap Karaarslan ◽  
Murat Zeytunlu ◽  
Murat Kilic ◽  
...  

1982 ◽  
Vol 12 (6) ◽  
pp. 456-462 ◽  
Author(s):  
Jiro Uozumi ◽  
Kazuyuki Sagiyama ◽  
Shun’ichiro Taniguchi ◽  
Yukihide Iwamoto ◽  
Ken Aoki ◽  
...  

2017 ◽  
Vol 47 (7) ◽  
pp. 616-621 ◽  
Author(s):  
Susumu Eguchi ◽  
Takanobu Hara ◽  
Mitsuhisa Takatsuki

Sign in / Sign up

Export Citation Format

Share Document